Combining two drugs, i.e. difluoromethylornithine and sulindac, at low doses has been shown, for the first time, to provide both great efficacy and great safety for clinical colon cancer prevention.
Related Articles
Impact Factor
Failure of bevacizumab in early-stage colon cancer
Featured
Hereditary mutations in cancer: the use of panels and genetic counselling
Senza categoria
Leave a Reply